Efficacy and perioperative effect of docetaxel plus oxaliplatin and S-1 in treating advanced gastric cancer
10.3969/j.issn.1000-8179.2013.13.010
- VernacularTitle:多西他赛联合奥沙利铂及替吉奥治疗进展期胃癌的疗效及对围手术期影响
- Author:
Lin LIU
;
Xinhui YANG
;
Haijiang WANG
;
Dong YIN
;
Qisan WANG
;
Cheng LEI
;
Bo JIN
- Publication Type:Journal Article
- Keywords:
stomach neoplasm;
docetaxel;
oxaliplatin;
S-1;
neoadjuvant;
chemotherapy
- From:
Chinese Journal of Clinical Oncology
2013;(13):788-791
- CountryChina
- Language:Chinese
-
Abstract:
Objective: This study investigates the effect of docetaxel + oxaliplatin + S-1 (DOS program) in treating advanced gastric cancer and surgical safety assessment. Methods: Fifty patients with advanced gastric cancer admitted to the Department of Gastrointestinal Surgery, The Affiliated Tumor Hospital of Xinjiang Medical University between January 2011 and May 2012 were enrolled in this study. These patients were randomized into the observation arm (n=25) and the control group (n=25). The observer group was administered three cycles of chemotherapy using a DOS program before surgical treatment, whereas the control group underwent surgery. Results: Compared with the control group, the clinical response rate (64.0%), D2 lymph node dissection rate (88.0% vs. 64.0%), and R0 resection rate (92.0%vs. 68.0%) in the observation group were significantly higher (P<0.05). Moreover, the number of postoperative lymph node metastasis in the observation group was significantly less than that in the control group (3.2±2.5 vs. 6.3±2.9, P<0.05). The operative time (230.5 min±45.6 min vs. 205.6 min±42.4 min) and intra-operative blood loss (425.5 mL ±115.4 mL vs. 210.6 mL±125.6 mL) of the two groups were sta-tistically significantly different (P<0.05). The incidence of postoperative complications and lymph node sweeping number of the two groups showed no significant difference (19.6 ±2.8 vs. 21.2 ±2.0, P>0.05). The patients exhibited good tolerance to chemotherapy, with bone marrow suppression and gastrointestinal reactions as the main adverse effects. Conclusion:The DOS program is a highly efficient, advanced gastric cancer neoadjuvant chemotherapy. The program can improve patient survival and has good patient tolerance and compliance, good peri-operative safety, high R0 resection rate, and low postoperative lymph node metastasis rate.
